Mind Medicine MindMed Inc
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
DFTX$34.64-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(In thousands)
| Years Ended December 31, | ||||
|---|---|---|---|---|
| 2023 · 2022 | ||||
| Cash flows from operating activities | ||||
| Net loss | $(95,732) | $(56,796) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Stock-based compensation | 15,494 | 13,707 | ||
| Amortization of intangible assets | 3,162 | 3,180 | ||
| Unrealized foreign exchange | (363) | (148) | ||
| Issuance costs on liability classified warrants | — | 1,500 | ||
| Change in fair value of 2022 USD Financing Warrants | 6,636 | (7,843) | ||
| Other non-cash adjustments | 157 | 43 | ||
| Changes in operating assets and liabilities: | ||||
| Prepaid and other current assets | 39 | (260) | ||
| Other noncurrent assets | 51 | (180) | ||
| Accounts payable | 2,025 | (2,056) | ||
| Accrued expenses | 5,318 | (416) | ||
| Other liabilities, long-term | (1,152) | (870) | ||
| Net cash used in operating activities | (64,365) | (50,139) | ||
| Cash flows from financing activities | ||||
| Proceeds from credit facility | 15,000 | — | ||
| Payment of credit facility issuance costs | (844) | — | ||
| Proceeds from issuance of common shares, net of issuance costs | 7,529 | 42,297 | ||
| Proceeds from issuance of 2022 USD Financing Warrants | — | 17,747 | ||
| Payment of 2022 USD Financing Warrants issuance costs | — | (1,500) | ||
| Proceeds from exercise of warrants | 114 | 708 | ||
| Proceeds from exercise of options | 49 | 206 | ||
| Withholding taxes paid on vested restricted stock units | — | (407) | ||
| Net cash provided by financing activities | 21,848 | 59,051 | ||
| Effect of exchange rate changes on cash | 79 | (309) | ||
| Net (decrease)/increase in cash and cash equivalents | (42,438) | 8,603 | ||
| Cash and cash equivalents, beginning of year | 142,142 | 133,539 | ||
| Cash and cash equivalents, end of year | $99,704 | $142,142 | ||
| Supplemental Cash Flow Information | ||||
| Cash paid for interest | $534 | $ | - | |
| Supplemental Noncash Disclosures | ||||
| Unpaid issuance costs for credit facility | $128 | $ | - | |
| Conversion of 2022 USD Financing Warrants to common stock upon exercise of warrants | $64 | $ | - | |
| Proceeds from issuance of common shares under the at-the-market offering program in prepaid and other current assets | $294 | $ | - | |
| Right-of-use assets obtained in exchange of operating lease liabilities | $ | - | $194 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.